Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited.
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Strong immune response shown in both children and adolescents one month after booster dose in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15.
07.09.2023 - Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster .
Total revenues of €361.3 million in 2022 compared to €348.1 million in 2021 Driven by product sales of €114.8 million (82.3% increase compared to 2021), including €85.2 million of travel vaccine sales